

PRODUCT INFORMATION



LDL Receptor Rabbit Monoclonal Antibody (Clone 004)


Item No. 37076

Overview and Properties

Contents:	This vial contains 50 or 100 µl of protein A-affinity purified monoclonal antibody.
Synonyms:	LDLR, Low Density Lipoprotein Receptor
Immunogen:	Recombinant mouse LDLR
Cross Reactivity:	(+) LDLR
Species Reactivity:	(+) Mouse
Form:	Liquid
Storage:	-80°C (as supplied)
Stability:	≥1 year
Storage Buffer:	0.2 µm filtered solution in PBS
Clone:	004
Host:	Rabbit
Isotype:	IgG
Applications:	Immunocytochemistry (ICC) and immunofluorescence (IF). The recommended starting dilution is 1:20 for ICC and 1:100 for IF. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Image



Immunofluorescent labeling of mouse LDLR in RAW 264.7 cells labeled with LDL Receptor Rabbit Monoclonal Antibody. Cells were fixed with 4% PFA, blocked with 10% serum, and incubated with LDL Receptor Rabbit Monoclonal Antibody (Clone 004) at 4°C overnight using a dilution of 1:60. Then cells were stained with the Alexa Fluor®488-conjugated Goat Anti-rabbit IgG secondary antibody (green) and counterstained with DAPI (blue).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/07/202

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

LDL receptor (LDLR) is a cell surface glycoprotein that scavenges LDL from the blood and regulates plasma LDL levels.¹ It is composed of an N-terminal signal sequence, a ligand-binding domain, an EGF precursor homology domain, an O-linked glycosylation domain, a transmembrane region, and a C-terminal cytoplasmic tail. LDLR is primarily expressed in the liver but is also found in the adrenal cortex.² It mediates the endocytosis of LDL by binding to apolipoprotein E (ApoE) or ApoB on the LDL surface, thereby supplying cholesterol to cells.¹ Protein levels of LDLR are decreased in HepG2 cells expressing proprotein convertase subtilisin kexin 9 (PCSK9).³ Knockout of *Ldlr* increases plasma levels of cholesterol and triglycerides and induces the formation of atherosclerotic lesions in mice.⁴ Mutations in *LDLR* are associated with familial hypercholesterolemia.⁵ Cayman's LDL Receptor Rabbit Monoclonal Antibody (Clone 004) can be used for immunocytochemistry (ICC) and immunofluorescence (IF) applications.

References

1. Goldstein, J.L., Brown, M.S., Anderson, R.G.W., *et al.* Receptor-mediated endocytosis: Concepts emerging from the LDL receptor system. *Annu. Rev. Cell Biol.* **1**, 1-39 (1985).
2. Rudling, M.J., Reihner, E., Einarsson, K., *et al.* Low density lipoprotein receptor-binding activity in human tissues: Quantitative importance of hepatic receptors and evidence for regulation of their expression *in vivo*. *Proc. Natl. Acad. Sci. USA* **87(9)**, 3469-3473 (1990).
3. Benjannet, S., Rhainds, D., Essalmani, R., *et al.* NARC-1/PCSK9 and its natural mutants. Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. *J. Biol. Chem.* **279(47)**, 48865-48875 (2004).
4. Praticò, D., Tillmann, C., Zhang, Z.B., *et al.* Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. *Proc. Natl. Acad. Sci. USA* **98(6)**, 3358-3363 (2001).
5. Austin, M.A., Hutter, C.M., Zimmern, R.L., *et al.* Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. *Am. J. Epidemiol.* **160(5)**, 407-420 (2004).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM